ImmuPharma PLC Cash Flow Conversion Efficiency
ImmuPharma PLC cash flow conversion efficiency. Based on the latest financial reports, ImmuPharma PLC (IMM) has a cash flow conversion efficiency ratio of -2.979x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-1.00 Million ≈ $-122.04 USD) by net assets (GBX336.70K ≈ $40.97 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ImmuPharma PLC (2004–2024)
Cash flow conversion efficiency of ImmuPharma PLC from 2004 to 2024. This chart illustrates how ImmuPharma PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for ImmuPharma PLC for real-time trading data and today's change.
ImmuPharma PLC Cash Flow Conversion Ratio Explained
ImmuPharma PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ImmuPharma PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ImmuPharma PLC ranked by their cash flow conversion efficiency. Also see IMM company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Empresaria Group plc
LSE:EMR
|
0.171x |
|
Global PVQ SE
HM:QCE
|
3.126x |
|
TEVANO SYSTEMS HLDGS INC.
F:7RBA
|
N/A |
|
Aquila Energy Efficiency Trust PLC
LSE:AEET
|
-0.007x |
|
Premier Health of America Inc
V:PHA
|
-0.010x |
|
Realfiction Holding AB
ST:REALFI
|
-0.154x |
|
Tan Delta Systems PLC
LSE:TAND
|
-0.245x |
|
CARLYLE COMMODIT.CORP.
F:BJ4
|
-0.183x |
Annual Cash Flow Conversion Efficiency for ImmuPharma PLC (2004–2024)
The table below shows the annual cash flow conversion efficiency of ImmuPharma PLC from 2004 to 2024. Review ImmuPharma PLC free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX-542.86K ≈ $-66.05 |
GBX-1.77 Million ≈ $-215.25 |
3.259x | +352.29% |
| 2023-12-31 | GBX1.06 Million ≈ $128.52 |
GBX-1.36 Million ≈ $-166.01 |
-1.292x | -38.87% |
| 2022-12-31 | GBX2.52 Million ≈ $307.02 |
GBX-2.35 Million ≈ $-285.57 |
-0.930x | +15.06% |
| 2021-12-31 | GBX4.41 Million ≈ $536.99 |
GBX-4.83 Million ≈ $-588.06 |
-1.095x | -217.56% |
| 2020-12-31 | GBX9.65 Million ≈ $1.17K |
GBX-3.33 Million ≈ $-405.09 |
-0.345x | +56.96% |
| 2019-12-31 | GBX5.27 Million ≈ $641.11 |
GBX-4.22 Million ≈ $-513.62 |
-0.801x | -29.36% |
| 2018-12-31 | GBX7.62 Million ≈ $927.50 |
GBX-4.72 Million ≈ $-574.43 |
-0.619x | +49.93% |
| 2017-12-31 | GBX3.57 Million ≈ $434.91 |
GBX-4.42 Million ≈ $-537.91 |
-1.237x | -5.76% |
| 2016-12-31 | GBX5.55 Million ≈ $674.79 |
GBX-6.49 Million ≈ $-789.17 |
-1.170x | +52.34% |
| 2015-12-31 | GBX1.69 Million ≈ $205.67 |
GBX-4.15 Million ≈ $-504.74 |
-2.454x | -462.18% |
| 2014-12-31 | GBX5.71 Million ≈ $694.18 |
GBX-2.49 Million ≈ $-303.03 |
-0.437x | +39.73% |
| 2013-12-31 | GBX5.40 Million ≈ $657.48 |
GBX-3.91 Million ≈ $-476.20 |
-0.724x | -87.19% |
| 2012-12-31 | GBX8.42 Million ≈ $1.02K |
GBX-3.26 Million ≈ $-396.30 |
-0.387x | -43.72% |
| 2011-12-31 | GBX12.51 Million ≈ $1.52K |
GBX-3.37 Million ≈ $-409.67 |
-0.269x | +37.19% |
| 2010-12-31 | GBX15.97 Million ≈ $1.94K |
GBX-6.84 Million ≈ $-832.84 |
-0.429x | -164.78% |
| 2009-12-31 | GBX18.08 Million ≈ $2.20K |
GBX11.96 Million ≈ $1.46K |
0.662x | +389.02% |
| 2008-12-31 | GBX11.24 Million ≈ $1.37K |
GBX-2.57 Million ≈ $-313.06 |
-0.229x | +80.78% |
| 2007-12-31 | GBX3.05 Million ≈ $371.10 |
GBX-3.63 Million ≈ $-441.91 |
-1.191x | -239.23% |
| 2006-03-31 | GBX2.50 Million ≈ $304.66 |
GBX-879.00K ≈ $-106.95 |
-0.351x | -1391.04% |
| 2005-03-31 | GBX993.00K ≈ $120.82 |
GBX27.00K ≈ $3.29 |
0.027x | +2559.21% |
| 2004-03-31 | GBX978.00K ≈ $118.99 |
GBX1.00K ≈ $0.12 |
0.001x | -- |
About ImmuPharma PLC
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company's lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lup… Read more